ShareCompartir
Volume 10, Number 8—August 2004
Research
Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000
Dominique L. Monnet*, Fiona M. MacKenzie†
, José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
, José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
Figure 2
Figure 2. Examples of graphic exploration of the relationship between the monthly % methicillin-resistant Staphylococcus aureus (%MRSA) and the monthly use of individual classes of antimicrobials, Aberdeen Royal Infirmary, January 1996–December 2000 (THICK LINE, %MRSA; THIN LINE, Antimicrobial use, 5-month moving average, right Y-axis); A) penicillins with β-lactamase inhibitors, B) macrolides, C) third-generation cephalosporins, D) fluoroquinolones, E) tetracyclines, and F) aminoglycosides.
- Page created: March 01, 2011
- Page last updated: March 01, 2011
- Page last reviewed: March 01, 2011
- Centers for Disease Control and Prevention,
-
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)